혈액암 (AML/ALL)

558개 · ADC 890 · Antibody 4071 · CGT 2714 · 다음 갱신 D-5 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved558 programs
CGTLimited DatastaleMiltenyi Biotec, Inc.Phase 2

Chimeric Antigen Receptor (CAR, Chimeric Antigen Receptor, Chimeric Antigen Receptor (CAR) T-Cell Product (Autologous))

B-Cell Lymphoma; B Acute Lymphoblastic Leukemia · B-Cell Lymphoma

#B-CellLymphoma#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
CGTLimited DatastaleSouthwest Hospital, ChinaPhase 2

Chimeric Antigen Receptor Modified T cells Targeting CD19 (Chimeric Antigen Receptor Modified T cells Targeting CD19)

Leukemia; Lymphoma · CD19

#CD19#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 1Status Active
CGTLimited DatastaleNelson HamerschlakPhase 1

Chimeric antigen receptor T cells to be implemented in a "3 + 3" design on day 0 (Chimeric antigen receptor T cells to be implemented in a "3 + 3" design on day 0)

Acute Lymphoblastic Leukemia, in Relapse; Acute Lymphoblastic Leukemia Refractory · FRα

#FR#CGT#Phase1#cell-gene-therapy#CAR-T+5
Trials 1Status Recruiting
AntibodyLimited DatastaleIdris BahceApproved

durvalumab (Imfinzi, Consolidation durvalumab)

Non-small Cell Lung Cancer Stage III · Non-small Cell Lung Cancer Stage III

#Non-smallCellLungCancerStageIII#Antibody#Approved#monoclonal-antibody#Idris
Trials 1Status Recruiting
AntibodyLimited DatastaleUniversity of Texas Southwester…Phase 2

durvalumab (Imfinzi, Consolidative Durvalumab)

Non Small Cell Lung Cancer; Lung Cancer Stage III · Non Small Cell Lung Cancer

#NonSmallCellLungCancer#Antibody#Phase2#monoclonal-antibody#LungCancerStageIII+1
Trials 1Status Active
CGTLimited DatastaleWashington University School of…Phase 2

Cytokine-induced memory-like NK cells (Cytokine-induced memory-like NK cells)

Refractory Acute Myeloid Leukemia; Relapsed Acute Myeloid Leukemia · FRα

#FR#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 1Status Discontinued
AntibodyLimited DatastaleDong-A ST Co., Ltd.Phase 2

pembrolizumab (Keytruda, DA-4505 + Pembrolizumab)

Locally Advanced or Metastatic Solid Tumors · Locally Advanced or Metastatic Solid Tum

#LocallyAdvancedorMetastaticSolid#Antibody#Phase2#monoclonal-antibody#Dong-A
Trials 1Status Recruiting
AntibodyLimited DatastaleDizal PharmaceuticalsPhase 2

DZD9008 plus Bevacizumab (DZD9008 plus Bevacizumab)

Non-small Cell Lung Cancer · Non-small Cell Lung Cancer

#Non-smallCellLungCancer#Antibody#Phase2#monoclonal-antibody#Dizal
Trials 1Status Recruiting
AntibodyLimited DatastaleAssistance Publique - Hôpitaux …Phase 2

nivolumab (Opdivo, Decreasing starting times for beginning nivolumab, Time to Event Continual Reassessment Method (TITE-CRM, Decreasing starting times for beginning nivolumab (Time to Event Continual Reassessment Method (TITE-CRM) ))

B Acute Lymphoblastic Leukemia; Acute Lymphoblastic Leukemia, in Relapse · B Acute Lymphoblastic Leukemia

#BAcuteLymphoblasticLeukemia#Antibody#Phase2#monoclonal-antibody#AcuteLymphoblasticLeukemia+2
Trials 1Status Recruiting
AntibodyLimited DatastaleOncoMed Pharmaceuticals, Inc.Phase 1

Demcizumab (Demcizumab)

Locally Advanced or Metastatic Solid Tumors · Locally Advanced or Metastatic Solid Tum

#LocallyAdvancedorMetastaticSolid#Antibody#Phase1#monoclonal-antibody#OncoMed
Trials 1Status Active
AntibodyLimited DatastaleGilead SciencesPhase 2

DOM (Domvanalimab, Domvanalimab (DOM))

Lung Cancer; Advanced or Metastatic Non-Small-Cell Lung Cancer · Lung Cancer

#LungCancer#Antibody#Phase2#monoclonal-antibody#AdvancedorMetastaticNon-Small-Ce+1
Trials 1Status Recruiting
CGTLimited DatastaleBeijing GoBroad HospitalPhase 1

Donor-derived CD19 CAR Therapy Bridged Allo-HSCT and Sequential Donor-derived CD22 CAR Therapy (Donor-derived CD19 CAR Therapy Bridged Allo-HSCT and Sequential Donor-derived CD22 CAR Therapy)

B-cell Acute Lymphoblastic Leukemia; Acute Lymphoblastic Leukemia, in Relapse · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+5
Trials 1Status Recruiting
CGTLimited DatastaleGerman Cancer Research CenterPhase 1

Donor-derived CD34+ HSC with CRISPR/Cas9-mediated CD33 deletion (Donor-derived CD34+ HSC with CRISPR/Cas9-mediated CD33 deletion)

Relapsed/Refractory Acute Myeloid Leukemia (AML) · CD33

#CD33#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
AntibodyLimited DatastaleTesaro, Inc.Phase 3

TSR-042 (Dostarlimab, Dostarlimab (TSR-042))

Ovarian Neoplasms; Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma · Ovarian Neoplasms

#OvarianNeoplasms#Antibody#Phase3#monoclonal-antibody#Ovarian+2
Trials 1Status Recruiting
CGTLimited DatastaleBeijing Boren HospitalPhase 1

Dual CD33/CLL1 CAR T (Dual CD33/CLL1 CAR T)

Acute Myeloid Leukemia · CD33

#CD33#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Discontinued
CGTLimited DatastaleBeijing BiotechPhase 2

EB-DT-CAR-NK (Dual-target CAR-NK cells, Dual-target CAR-NK cells (EB-DT-CAR-NK))

Breast Cancer (Locally Advanced or Metastatic); HER2-positive Breast Cancer · HER2

#HER2#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleUniversity of Kansas Medical Ce…Phase 1

DuoCAR20.19.22-D95 (DuoCAR20.19.22-D95)

B-Cell Non-Hodgkin Lymphoma; B-cell Acute Lymphoblastic Leukemia · B-Cell Non-Hodgkin Lymphoma

#B-CellNon-HodgkinLymphoma#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
AntibodyLimited DatastaleCelgenePhase 2

Duravalumab (Duravalumab)

Carcinoma, Non-Small-Cell Lung · Carcinoma, Non-Small-Cell Lung

#CarcinomaNon-Small-CellLung#Antibody#Phase2#monoclonal-antibody#Carcinoma+2
Trials 1Status Active
CGTLimited DatastaleBeijing BiotechPhase 2

DLL3/CD56 CAR-NK cells (EB-DART-NK01, EB-DART-NK01 (DLL3/CD56 CAR-NK cells))

Small Cell Lung Cancer (SCLC); Relapsed/Refractory SCLC · FRα

#FR#CGT#Phase2#cell-gene-therapy#CAR-T+5
Trials 1Status Recruiting
CGTLimited DatastaleBeijing BiotechPhase 2

MSLN + MUC1 (EB-DNK101 dual-targeting CAR-NK cells, EB-DNK101 dual-targeting CAR-NK cells (MSLN + MUC1))

Pancreatic Ductal Adenocarcinoma (PDAC); Unresectable Locally Advanced or Metastatic Disease · Pancreatic Ductal Adenocarcinoma (PDAC)

#PancreaticDuctalAdenocarcinomaPD#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting

19 / 28 pages

← PreviousNext →